Nereid Therapeutics will advance research by Clifford Brangwynne of Princeton University following its launch with a $50m series A round from Apple Tree Partners.
Nereid Therapeutics, a US-based developer of treatments for cancer and neurodegenerative diseases based on research at Princeton University, was launched this week by venture firm Apple Tree Partners with $50m in series A capital.
Nereid will develop therapies targeting biomolecular condensates, a specialised subunit of the cell, using research by scientific founder Clifford Brangwynne, a professor in the Department of Chemical and Biological Engineering at Princeton University and an investigator at the Howard Hughes Medical Institute.
Brangwynne’s work…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
